Strategic Partners Olaris has attracted strategic investments from Labcorp and Bruker, highlighting potential for co-development, validation partnerships, and market access opportunities for myOLARIS diagnostics in translational and clinical settings.

Transplant Focus Active engagement in transplant research and non-invasive urine assays for graft injury and immune status positions Olaris to target transplant centers, nephrology networks, and pharma sponsors focusing on organ rejection monitoring and immunosuppression optimization.

Derm & Neuro Expansion Current indication scope includes oncology, neurodegeneration, and solid-organ transplant, suggesting cross-indication selling opportunities with CROs and biopharma clients pursuing metabolomics-driven patient stratification and companion diagnostics.

KT Diagnostics Launch of myOLARIS-KT dx and focus on kidney transplant risk assessment creates upsell potential for nephrology clinics, transplant boards, and LAB stakeholders seeking non-invasive monitoring tools to reduce complications.

Data-Driven Sales Investments in metabolomics and machine learning, combined with cloud-based analytics and demonstrated study posters at ATC conferences, provide evidence for ROI-focused pitches to pharma sponsors seeking precision diagnostics to optimize therapies.